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Objective: To study the effect of sitagliptin on adipocytokines expression in diabetic rats
and its molecular mechanism.
Methods: Male SD rats were chosen and randomly divided into NC group, T2DM
group, SP group and SP + LY group. NC group received conventional breeding, T2DM
group, SP group and SP + LY group received intraperitoneal injection of streptozotocin
after 12 weeks of high-fat diet to establish diabetes animal model, SP group received
sitagliptin intervention and SP + LY group received sitagliptin combined with PI3K
inhibitor LY294002 intervention. Six weeks after the intervention, serum was collected to
determine the levels of biochemical indexes and adipocytokines, and visceral adipose
tissue was collected to determine expression levels of adipocytokines.
Results: Serum TC, TG, LDL-C, FBG, FINS, Leptin and Chemerin levels as well as
HOMA-IR of T2DM group were higher than those of NC group, and HDL-C, Adipo-
nectin and Omentin-1 levels were signiﬁcantly lower than those of NC group; serum TC,
TG, LDL-C, FBG, FINS, Leptin and Chemerin levels as well as HOMA-IR of SP group
were lower than those of T2DM group, and HDL-C, Adiponectin and Omentin-1 levels
were signiﬁcantly higher than those of T2DM group; Leptin and Chemerin levels in
serum and visceral adipose tissue of SP + LY group were higher than those of SP group
while Adiponectin and Omentin-1 levels were signiﬁcantly lower than those of SP group.
Conclusion: Sitagliptin can regulate the expression of adipocytokines in adipose tissue
of diabetic rats through PI3K-AKT pathway.1. Introduction
Type 2 diabetes mellitus (T2DM) is an endocrine disease
characterized by insulin resistance and relatively insufﬁcient
insulin secretion, is with rising morbidity, and causes adverse
effect on both life health and quality of life of the patients.
Adipocytokines are a type of cytokines synthesized and secreted
by adipocytes, include Adiponectin, Leptin, (Omentin-1),
Chemerin, etc., and have regulating effect on inﬂammation, in-
sulin sensitivity, endothelial function, etc [1,2]. There are
abnormal glucolipid metabolism and abnormal abdominal
visceral adipose tissue accumulation in T2DM patients, andthe adipocytokines synthesized by visceral adipose tissue will
change, resulting in a variety of diabetic complications [3–5].
Sitagliptin is an oral hypoglycemic drug used in treatment of
T2DM patients in recent years, belongs to the dipeptidyl
peptidase-4 (DPP-4) inhibitor, and can inhibit glucagon-like
peptide (GLP-1) degradation, regulate insulin sensitivity and
lower blood glucose [6,7]. At present, the regulating effect of
sitagliptin on adipocytokines in patients with T2DM is
unclear. In the following study, the diabetic rat models were
established and the changes of adipocytokines after sitagliptin
treatment were analyzed.
2. Materials and methods
2.1. Experimental materials
Experimental animals were 50 male SD rats with 6–8 weeks
of age and body mass of 160–220 g, they were purchased fromess article under the CC BY-NC-ND license
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cense No. was SCXK 2008-0016, the animal study was
approved by the hospital ethics committee; streptozotocin and
PI3K inhibitor LY294002 were from Sigma Company, enzyme-
linked immunosorbent assay kits were from Elabscience Com-
pany, and RNA extraction kits, the ﬁrst strand of cDNA syn-
thesis kits and ﬂuorescence quantitative PCR kits were from
Beijing Tiangen Biochemical Company. OneTouch Ultra for
Johnson & Johnson Company, microplate reader was from the
Bio-rad Company, and fully automatic biochemical analyzer
was from Switzerland Roche Company.
2.2. Experimental methods
2.2.1. Animal grouping and model establishing methods
Experimental animals were randomly divided into NC group,
T2DM group, SP group and SP + LY group. NC group (n = 8)
received conventional breeding, the remaining 42 were used for
T2DM model establishment, and the method was as follows:
they received high-fat diet for 12 weeks, and then were given
intraperitoneal injection of 35 mg/kg streptozotocin, streptozo-
tocin was temporarily conﬁgured with pH = 4.5 0.1 mmol/L
sodium citrate buffer before injection, blood was collected via
caudal vein 7 days after injection, rats with fasting
glucose > 11.1 mmol/L were considered as successfully estab-
lished, 5 were dead, 7 were with substandard fasting glucose,
and only 30 were successfully established and randomly divided
into T2DM group, SP group and SP + LY group, 10 in each
group.
2.2.2. Intervention methods
T2DM group received intragastric administration of
hydroxymethyl amylase, 2 mL/time, 1 time/day, and then
continued to receive normal diet; SP group received intragastric
administration of sitagliptin, 10 mg/(kg$d), the sitagliptin was
dissolved in 2 ml hydroxymethyl amylase, and after interven-
tion, they continued to receive normal diet; SP + LY group
received intragastric administration of sitagliptin with the same
method as that of SP group and received subcutaneous injection
of PI3K inhibitor LY294002, 50 mg/(kg$d), LY294002 was
dissolved in 1 mL saline, and after intervention, they continued
to receive normal diet.
2.2.3. Sample collecting methods
Six weeks after intervention, four groups of rats were fasting
for 12 h and then was sacriﬁced by cervical dislocation, blood
samples were collected, let stand for 15 min at room temperature
and then centrifuged in the centrifugal machine for 10 min at
3000 r/min, and serum was separated and saved at −80 C;Table 1
Serum biochemical indexes of all groups.
Group n TC (mmol/L) TG (mmol/L) LDL-C (mmol/L)
NC group 8 1.74 ± 0.25 0.72 ± 0.10 0.97 ± 0.12
T2DM group 10 2.95 ± 0.32△ 1.32 ± 0.18△ 1.93 ± 0.25△
SP group 10 2.04 ± 0.31: 0.89 ± 0.11: 1.21 ± 0.18:
SP + LY group 10 2.77 ± 0.35* 1.25 ± 0.22* 1.82 ± 0.26*
△P < 0.05 compared with NC group; :P < 0.05 compared with T2DM grabdominal cavity of rats was opened after execution, abdominal
visceral adipose tissue was collected, frozen with liquid nitrogen
and then saved at −80 C.
2.2.4. Index detecting methods
Serum specimen were collected, automatic biochemical
analyzer was used to determine fasting blood glucose (FBG),
fasting blood insulin (FINS), total cholesterol (TC), triglyceride
(TG), low-density lipoprotein cholesterol (LDL-C), high-density
lipoprotein cholesterol (HDL-C) content, and the steady-state
model was used to calculate the insulin resistance index
(HOMA-IR) = FINS × FBG/22.5. Enzyme-linked immunosor-
bent assay kits were used to determine Adiponectin, Leptin,
Omentin-1 and Chemerin levels. Abdominal visceral adipose
tissue was collected, RNA extraction kits and the ﬁrst strand of
cDNA synthesis kits were used to separate and obtain cDNA
samples, then ﬂuorescent quantitative PCR ampliﬁcation was
performed, and the mRNA levels of Adiponectin, Leptin,
Omentin-1 and Chemerin were calculated.
2.2.5. Statistical methods
SPSS20.0 software was used to input and analyze data,
measurement data was by variance analysis, pair-wise compar-
ison was by LSD-t test and P < 0.05 indicated statistical sig-
niﬁcance in differences.
3. Results
3.1. Serum biochemical indexes of all groups
Serum biochemical indexes TC, TG, LDL-C, HDL-C, FBG
and FINS as well as HOMA-IR of NC group, T2DM group, SP
group and SP + LY group were signiﬁcant different (P < 0.05),
and pair-wise comparison and analysis showed that: serum TC,
TG, LDL-C, FBG and FINS levels as well as HOMA-IR of
T2DM group were higher than those of NC group, and HDL-C
was signiﬁcantly lower than that of NC group; serum TC, TG,
LDL-C, FBG and FINS levels as well as HOMA-IR of SP group
were lower than those of T2DM group, and HDL-C was
signiﬁcantly higher than that of T2DM group; serum TC, TG,
LDL-C, FBG and FINS levels as well as HOMA-IR of SP + LY
group were higher than those of SP group, and HDL-C was
signiﬁcantly lower than that of SP group (Table 1).
3.2. Effect of sitagliptin intervention on serum levels of
adipocytokines in T2DM rats
Serum adipocytokines Adiponectin, Leptin, Omentin-1 and
Chemerin levels of NC group, T2DM group and SP group wereHDL-C (mmol/L) FBG (mmol/L) FINS (IU/mL) HOMA-IR
0.82 ± 0.10 4.89 ± 0.74 6.14 ± 0.89 1.62 ± 0.22
0.45 ± 0.07△ 13.20 ± 1.85△ 17.58 ± 2.51△ 8.48 ± 1.03△
0.74 ± 0.09: 5.85 ± 0.71: 8.39 ± 1.05: 3.38 ± 0.44:
0.56 ± 0.07* 12.14 ± 1.88* 14.59 ± 2.35* 7.14 ± 0.91*
oup; *P < 0.05 compared with SP group.
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analysis showed that serum Adiponectin and Omentin-1 levels
of T2DM group were signiﬁcantly lower than those of NC group
while Leptin and Chemerin levels were signiﬁcantly higher than
those of NC group; serum Adiponectin and Omentin-1 levels of
SP group were signiﬁcantly higher than those of T2DM group
while Leptin and Chemerin levels were signiﬁcantly lower than
those of T2DM group (Table 2).Table 2
Effect of sitagliptin intervention on serum levels of adipocytokines in T2DM rats.
Group Sample size Adiponectin (mg/mL) Leptin (mg/mL) Omentin-1 (mg/mL) Chemerin (pg/mL)
NC group 8 11.48 ± 1.67 4.22 ± 0.92 22.42 ± 4.85 451.24 ± 67.13
T2DM group 10 6.42 ± 8.10△ 14.12 ± 1.86△ 8.92 ± 1.06△ 792.32 ± 92.42△
SP group 10 10.14 ± 1.52: 6.79 ± 0.91: 17.85 ± 2.86: 527.85 ± 71.45:
△P < 0.05 compared with NC group, there were differences; :P < 0.05 compared with T2DM group.3.3. Effect of sitagliptin intervention on the expression of
adipocytokines in visceral adipose tissue of T2DM rats
Adipocytokines Adiponectin, Leptin, Omentin-1 and Chem-
erin levels in visceral adipose tissue of NC group, T2DM group
and SP group were signiﬁcantly different (P < 0.05), and pair-
wise comparison and analysis was as follows: Adiponectin
and Omentin-1 levels in visceral adipose tissue of T2DM group
were signiﬁcantly lower than those of NC group while Leptin
and Chemerin levels were signiﬁcantly higher than those of NC
group; Adiponectin and Omentin-1 levels in visceral adipose
tissue of SP group were signiﬁcantly higher than those of T2DM
group while Leptin and Chemerin levels were signiﬁcantly
lower than those of T2DM group (Table 3).Table 3
Effect of sitagliptin intervention on the mRNA levels of adipocytokines
in visceral adipose tissue of T2DM rats.
Group n Adiponectin Leptin Omentin-1 Chemerin
NC
group
8 1.00 ± 0.15 1.00 ± 0.17 1.00 ± 0.13 1.00 ± 0.14
T2DM
group
10 0.38 ± 0.07△ 2.42 ± 0.37△ 0.32 ± 0.06△ 2.71 ± 0.33△
SP
group
10 0.84 ± 0.11: 1.32 ± 0.19: 0.89 ± 0.12: 1.52 ± 0.22:
△P < 0.05 compared with NC group, there were differences; :P < 0.05
compared with T2DM group.3.4. Effect of PI3K inhibitor combined with sitagliptin
on the generation of adipocytokines
Serum Leptin and Chemerin levels in serum and visceral
adipose tissue of SP + LY group were higher than those of SPTable 4
Effect of PI3K inhibitor combined with sitagliptin on the generation of adip
Group n Serum samples
Adiponectin
(mg/mL)
Leptin (mg/
mL)
Omentin-1 (mg/
mL)
Chemeri
mL
SP group 10 10.14 ± 1.52 6.79 ± 0.91 17.85 ± 2.86 527.85 ±
SP + LY
group
10 7.14 ± 0.88* 12.84 ± 2.42* 10.33 ± 1.93* 745.23 ±
*P < 0.05, compared with SP group.group while Adiponectin and Omentin-1 levels were signiﬁ-
cantly lower than those of SP group (Table 4).
4. Discussion
Insulin resistance and relatively insufﬁcient secretion are the
most prominent pathological features of T2DM, and increasing
insulin sensitivity and promoting insulin secretion or supple-menting exogenous insulin are important in the clinical treat-
ment of T2DM. GLP-1 is a polypeptide hormone newly
discovered in recent years, and it can lower the blood glucose by
promoting insulin secretion, restraining glucagon secretion,
slowing gastric emptying and other ways [8,9]. Under
physiological conditions, GLP-1 can be rapidly degraded by
DPP-4 and lose biological activity. Sitagliptin is a highly se-
lective inhibitor of DPP-4 that can increase the GLP-1 levels in
the body and regulate blood glucose metabolism [10,11]. In order
to specify the value of sitagliptin for treatment of diabetes, high-
fat diet combined with intraperitoneal injection of streptozotocin
was adopted in the study to establish the diabetic animal models,
and the analysis of blood glucose metabolism indexes showed
that serum FBG and FINS levels as well as HOMA-IR of T2DM
group were higher than those of NC group. Thus it conﬁrmed
that the diabetic models were successfully established, and there
were hyperglycemia, hyperinsulinism and insulin resistance in
model rats. After sitagliptin treatment, serum FBG and FINS
levels as well as HOMA-IR of SP group were lower than those
of T2DM group. This meant that sitagliptin treatment could
improve the insulin resistance and reduce blood glucose levels in
diabetic rats.
In progression of diabetes, abnormal glucose metabolism and
hyperinsulinemia will affect lipid metabolism, cause elevated
blood lipid levels and promote fat deposition in abdominal
visceral tissue [12–14]. Elevated blood lipid level is the risk factor
causing atherosclerosis, and is also one of the reasons for the
increased risk of diabetic macro-vascular complications. In the
study, the analysis of blood lipid metabolism conﬁrmed that
serum TC, TG and LDL-C levels of T2DM group were higher
than those of NC group and HDL-C level was lower than that of
NC group; after sitagliptin intervention, serum TC, TG and
LDL-C levels of SP group were lower than those of T2DMocytokines.
Visceral adipose tissue
n (pg/
)
Adiponectin/
GAPDH
Leptin/
GAPDH
Omentin-1/
GAPDH
Chemerin/
GAPDH
71.45 0.84 ± 0.11 1.32 ± 0.19 0.89 ± 0.12 1.52 ± 0.22
94.42* 0.49 ± 0.08* 2.10 ± 0.27* 0.44 ± 0.07* 2.21 ± 0.27*
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This meant that there was abnormal blood lipid metabolism in
diabetic models, and sitagliptin intervention could improve
blood lipid metabolism.
Studies in recent years believe that adipocytokines that are
synthesized and secreted by adipocytes have important regu-
lating effect on insulin sensitivity, endothelial function and
inﬂammation, etc, and the abnormal blood lipid metabolism and
excessive fat deposition in T2DM rats can lead to abnormal
synthesis and secretion of adipocytokines [15,16]. In the study,
detection of adipocytokines Adiponectin, Leptin, Omentin-1
and Chemerin levels showed that Adiponectin and Omentin-1
levels in serum and visceral adipose tissue of T2DM group
were signiﬁcantly lower than those of NC group while Leptin
and Chemerin levels were signiﬁcantly higher than those of NC
group. Adiponectin has anti-inﬂammation, anti-atherosclerosis
and endothelium-protective effect [17], and Omentin-1 can in-
crease insulin sensitivity [18]; Leptin has the function of
antagonizing the biological activity of insulin and can lead to
insulin resistance and cause endothelial function damage [19],
and Chemerin can reduce insulin sensitivity and restrain
glucose uptake and utilization of peripheral tissue [20]. The
decrease of Adiponectin and Omentin-1 as well as the increase
of Leptin and Chemerin in diabetic rats is associated with insulin
resistance and the occurrence of endothelial injury and athero-
sclerosis. After sitagliptin intervention, Adiponectin and
Omentin-1 levels in serum and visceral fat tissue of SP group
were signiﬁcantly higher than those of T2DM group while
Leptin and Chemerin levels were signiﬁcantly lower than those
of T2DM group. This meant that sitagliptin could regulate the
synthesis of adipocytokines in visceral adipose tissue of diabetic
rats.
Phosphatidylcholine 3-kinase (PI3K)-protein kinase B (PKB/
AKT) is an important signal pathway mediating the biological
signal of insulin in vivo, the activation of PI3K can cause the
phosphorylation of the third hydroxyl in inositol ring, and
phosphatidyl inositol diphosphate is transformed into phospha-
tidyl inositol triphosphate (PIP3) that has the function of second
messenger. PIP3 is combined with AKT N-terminal and causes
its conformational change, and then activates downstream nu-
clear transcription factor NF-kB and regulates the expression of
multiple genes [21,22]. In order to deﬁne whether sitagliptin
regulated the expression of adipocytokines by PI3K-AKT
signaling pathways, PI3K antagonist LY294002 combined
with sitagliptin treatment was adopted in the study, and
compared with SP group, Adiponectin and Omentin-1 levels in
serum and visceral fat tissue of LY group decreased signiﬁcantly
while Leptin and Chemerin levels increased signiﬁcantly. This
meant that the effect of sitagliptin on regulating adipocytokines
could be partially reversed by PI3K antagonist LY294002, and
thus also conﬁrmed that sitagliptin could regulate the expression
of adipocytokines in visceral adipose tissue through PI3K-AKT
signaling pathway.
To sum up, the expression of adipocytokines is signiﬁcantly
abnormal in visceral adipose tissue of diabetic rats, and sita-
gliptin can regulate the expression of adipocytokines in adipose
tissue of diabetic rats through PI3K-AKT pathway.
References
[1] Adamiak P, Łącka K. Adipose tissue, adipokines and aging. Pol
Merkur Lek 2016; 40(236): 122-128.[2] Mansur RB, Rizzo LB, Santos CM, Asevedo E, Cunha GR,
Noto MN, et al. Adipokines, metabolic dysfunction and illness
course in bipolar disorder. J Psychiatr Res 2016m; 74: 63-79.
[3] Bjornstad P, Truong U, Dorosz JL, Cree-Green M, Baumgartner A,
Coe G, et al. Cardiopulmonary dysfunction and adiponectin in
adolescents with type 2 diabetes. J Am Heart Assoc 2016; 4(3):
e002804.
[4] Barbarash O, Gruzdeva O, Uchasova E, Dyleva Y, Belik E,
Akbasheva O, et al. The role of adipose tissue and adipokines in
the manifestation of type 2 diabetes in the long-term period
following myocardial infarction. Diabetol Metab Syndr 2016;
17(8): 24.
[5] Olarescu NC, Bollerslev J. The impact of adipose tissue on insulin
resistance in acromegaly. Trends Endocrinol Metab 2016; 27(4):
226-237.
[6] Wu WL, Hao J, Domalski M, Burnett DA, Pissarnitski D, Zhao Z,
et al. Discovery of novel tricyclic heterocycles as potent and se-
lective DPP-4 inhibitors for the treatment of type 2 diabetes. ACS
Med Chem Lett 2016; 7(5): 498-501.
[7] Bonora E, Cigolini M. DPP-4 inhibitors and cardiovascular disease
in type 2 diabetes mellitus. Expectations, observations and per-
spectives. Nutr Metab Cardiovasc Dis 2016; 26(4): 273-284.
[8] Linnemann AK, Davis DB. Glucagon-like peptide-1 and chole-
cystokinin production and signaling in the pancreatic islet as an
adaptive response to obesity. J Diabetes Investig 2016; 7(Suppl 1):
44-49.
[9] Arau´jo F, Shrestha N, Gomes MJ, Herranz-Blanco B, Liu D,
Hirvonen JJ, et al. In vivo dual-delivery of glucagon like peptide-1
(GLP-1) and dipeptidyl peptidase-4 (DPP4) inhibitor through
composites prepared by microﬂuidics for diabetes therapy. Nano-
scale 2016; 8(20): 10706-10713.
[10] Fukui K, Kawahito H, Wakana N, Kikai M, Terada K,
Yamamoto K, et al. Dipeptidyl peptidase-4 inhibitor sitagliptin
improves pancreatic b-cell function in hypertensive diabetic pa-
tients treated with angiotensin receptor blockers. J Renin Angio-
tensin Aldosterone Syst 2015; 16(4): 1001-1009.
[11] Umezawa S, Kubota A, Maeda H, Kanamori A, Matoba K, Jin Y,
et al. Two-year assessment of the efﬁcacy and safety of sitagliptin
in elderly patients with type 2 diabetes: post hoc analysis of the
ASSET-K study. BMC Endocr Disord 2015; 3(15): 34.
[12] Fang L, Guo F, Zhou L, Stahl R, Grams J. The cell size and dis-
tribution of adipocytes from subcutaneous and visceral fat is
associated with type 2 diabetes mellitus in humans. Adipocyte
2015; 4(4): 273-279.
[13] Taira S, Shimabukuro M, Higa M, Yabiku K, Kozuka C, Ueda R,
et al. Lipid deposition in various sites of the skeletal muscles and
liver exhibits a positive correlation with visceral fat accumulation
in middle-aged Japanese men with metabolic syndrome. Intern
Med 2013; 52(14): 1561-1571.
[14] Wang Z, Zeng X, Chen Z, Wang X, Zhang L, Zhu M, et al. As-
sociation of visceral and total body fat with hypertension and
prehypertension in a middle-aged Chinese population. J Hypertens
2015; 33(8): 1555-1562.
[15] Boulet MM, Chevrier G, Grenier-Larouche T, Pelletier M,
Nadeau M, Scarpa J, et al. Alterations of plasma metabolite proﬁles
related to adipose tissue distribution and cardiometabolic risk. Am J
Physiol Endocrinol Metab 2015; 309(8): 736-746.
[16] Yanai H, Hirowatari Y. Different associations of body mass index
and visceral fat area with metabolic parameters and adipokines in
Japanese patients with type 2 diabetes. Diabetes Metab 2015;
41(3): 261-262.
[17] Eslamian M, Mohammadinejad P, Aryan Z, Nakhjavani M,
Esteghamati A. Positive correlation of serum adiponectin with lipid
proﬁle in patients with type 2 diabetes mellitus is affected by
metabolic syndrome status. Arch Iran Med 2016; 19(4): 269-274.
[18] Zhang Q, Zhu L, Zheng M, Fan C, Li Y, Zhang D, et al. Changes
of serum omentin-1 levels in normal subjects, type 2 diabetes and
type 2 diabetes with overweight and obesity in Chinese adults. Ann
Endocrinol (Paris) 2014; 75(3): 171-175.
[19] Ayina CN, Noubiap JJ, Etoundi Ngoa LS, Boudou P, Gautier JF,
Mengnjo MK, et al. Association of serum leptin and adiponectin
Qiao-Min Wu et al./Asian Paciﬁc Journal of Tropical Medicine 2016; 9(9): 893–897 897with anthropomorphic indices of obesity, blood lipids and insulin
resistance in a Sub-Saharan African population. Lipids Health Dis
2016; 15(1): 96.
[20] Li Y, Shi B, Li S. Association between serum chemerin concen-
trations and clinical indices in obesity or metabolic syndrome: a
meta-analysis. PLoS One 2014; 9(12): e113915.[21] Mishra J, Verma RK, Alpini G, Meng F, Kumar N. Role of Janus
kinase 3 in predisposition to obesity-associated metabolic syn-
drome. J Biol Chem 2015; 290(49): 29301-29312.
[22] Li S, Chen H, Wang J, Wang X, Hu B, Lv F. Involvement of the
PI3K/Akt signal pathway in the hypoglycemic effects of tea poly-
saccharides on diabeticmice. Int J BiolMacromol 2015; 81: 967-974.
